4D Molecular Therapeutics, Inc. (FDMT)Healthcare | Biotechnology | EmeryVille, United States | NasdaqGS
11.30 USD
-1.01
(-8.205%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 11.26 -0.04 (-0.035%) ⇩ (July 13, 2026, 7:23 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:23 a.m. EDT
The investment case for this biotech firm is currently broken by a catastrophic multi-year price collapse and deteriorating operational metrics. Despite a recent 7.9% price bounce, the underlying business is bleeding cash aggressively, with gross margins of -145% and operating cash flow of -$129 million, while revenue growth figures are likely distorted by base effects following a massive drop in the previous year. The balance sheet, while showing low debt, is propped up by a massive cash pile that is being consumed rapidly by losses. The options market confirms this distress, with traders buying deep out-of-the-money puts as insurance against further ruin rather than betting on recovery. While analysts maintain a 'Buy' rating based on potential future clinical success, the current reality is a company in a death spiral where the market has already priced out any hope of a quick turnaround. The recent price action is a technical bounce off a floor, not a sign of renewed life. |
| Model | MAE |
|---|---|
| MSTL_90 ✓ | 0.095526 |
| MSTL | 0.102008 |
| AutoETS | 0.102482 |
| AutoARIMA | 0.102483 |
| AutoTheta | 0.105442 |
| MSTL_115 | 0.131935 |
| MSTL_90_115 | 0.151121 |
Forecast horizon: 60 days | Selected: MSTL_90
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 3.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.123 |
| Excess Kurtosis | -1.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.545 |
| Revenue per Share | 1.446 |
| Market Cap | 590,721,728 |
| Forward P/E | -3.03 |
| Beta | 2.69 |
| Profit Margins | -182.34% |
| Website | https://www.4dmoleculartherapeutics.com |
As of July 11, 2026, 3:23 a.m. EDT: Speculators are overwhelmingly positioned for downside protection, with zero in-the-money put volume recorded across all expirations and significant open interest concentrated in deep out-of-the-money strikes (below $8). Call activity is sparse and dominated by deep in-the-money positions, suggesting minimal speculative leverage for upside moves. Implied volatility is elevated relative to the low option premium, indicating a market pricing in binary downside events rather than steady appreciation.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8105023 |
| Address1 | 5,858 Horton Street |
| Address2 | Suite 455 |
| All Time High | 55.11 |
| All Time Low | 2.235 |
| Ask | 14.42 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 1,202,540 |
| Average Daily Volume3 Month | 872,772 |
| Average Volume | 872,772 |
| Average Volume10Days | 1,202,540 |
| Beta | 2.691 |
| Bid | 8.64 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 8.644 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.3 |
| Current Ratio | 9.339 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 12.12 |
| Day Low | 11.23 |
| Debt To Equity | 4.545 |
| Display Name | 4D Molecular Therapeutics |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -171,434,000 |
| Ebitda Margins | -1.9427699 |
| Enterprise To Ebitda | -1.285 |
| Enterprise To Revenue | 2.497 |
| Enterprise Value | 220,364,672 |
| Eps Current Year | -3.92511 |
| Eps Forward | -3.725 |
| Eps Trailing Twelve Months | -2.57 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.1339 |
| Fifty Day Average Change | 1.1661005 |
| Fifty Day Average Change Percent | 0.11506928 |
| Fifty Two Week Change Percent | 181.05023 |
| Fifty Two Week High | 14.0 |
| Fifty Two Week High Change | -2.6999998 |
| Fifty Two Week High Change Percent | -0.19285713 |
| Fifty Two Week Low | 4.11 |
| Fifty Two Week Low Change | 7.19 |
| Fifty Two Week Low Change Percent | 1.7493917 |
| Fifty Two Week Range | 4.11 - 14.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,697,000,000 |
| Float Shares | 38,950,514 |
| Forward Eps | -3.725 |
| Forward P E | -3.0335572 |
| Free Cashflow | -69,357,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 196 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.45662 |
| Gross Profits | -128,535,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03323 |
| Held Percent Institutions | 0.98407 |
| Implied Shares Outstanding | 52,276,254 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California. |
| Long Name | 4D Molecular Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 590,721,728 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_272879653 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -160,896,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 643,520,686 |
| Number Of Analyst Opinions | 9 |
| Open | 12.0 |
| Operating Cashflow | -129,449,000 |
| Operating Margins | -24.16147 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 510 505 2680 |
| Post Market Change | -0.03540039 |
| Post Market Change Percent | -0.31327778 |
| Post Market Price | 11.2646 |
| Post Market Time | 1,783,984,981 |
| Previous Close | 12.31 |
| Price Eps Current Year | -2.8789003 |
| Price Hint | 2 |
| Price To Book | 1.3072652 |
| Price To Sales Trailing12 Months | 6.6943374 |
| Profit Margins | -1.82336 |
| Quick Ratio | 9.006 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.54545 |
| Region | US |
| Regular Market Change | -1.01 |
| Regular Market Change Percent | -8.20471 |
| Regular Market Day High | 12.12 |
| Regular Market Day Low | 11.23 |
| Regular Market Day Range | 11.23 - 12.12 |
| Regular Market Open | 12.0 |
| Regular Market Previous Close | 12.31 |
| Regular Market Price | 11.3 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 630,928 |
| Return On Assets | -0.2143 |
| Return On Equity | -0.34917998 |
| Revenue Growth | 216.643 |
| Revenue Per Share | 1.446 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 52,276,254 |
| Shares Percent Shares Out | 0.2545 |
| Shares Short | 13,305,097 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,191,854 |
| Short Name | 4D Molecular Therapeutics, Inc. |
| Short Percent Of Float | 0.2942 |
| Short Ratio | 11.9 |
| Source Interval | 15 |
| State | CA |
| Symbol | FDMT |
| Target High Price | 36.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 28.22222 |
| Target Median Price | 29.0 |
| Total Cash | 390,892,000 |
| Total Cash Per Share | 7.477 |
| Total Debt | 20,535,000 |
| Total Revenue | 88,242,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.617425 |
| Two Hundred Day Average Change | 1.6825752 |
| Two Hundred Day Average Change Percent | 0.1749507 |
| Type Disp | Equity |
| Volume | 630,928 |
| Website | https://www.4dmoleculartherapeutics.com |
| Zip | 94,608 |